Reata CEO Warren Huff

Biogen To Acquire Plano-Based Biotech Reata Pharmaceuticals

by | Jul 28, 2023
Founded in 2002, rare disease drugmaker Reata has made significant advances in therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. The company's FDA-approved SKYCLARYS is the first and only approved treatment in the U.S. for Friedreich’s ataxia, a genetic nervous system disorder.
Soleo Health Selected as Sole Specialty Pharmacy Distributor of Newly FDA-Approved Alzheimer’s Treatment
by | Jan 18, 2023
Frisco-based pharmacy services provider Soleo Health has been selected by Eisai Inc. as the sole specialty pharmacy distribution partner for Leqembi (lecanemab-irmb), a newly FDA-approved treatment for early and mild stages of Alzheimer’s Disease. Soleo Health CEO Drew Walk says the partnership "will afford the Alzheimer’s community continued hope while we assist patients and their caregivers as they navigate their healthcare journey."